We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+6.12%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.93B
AUM Growth
-$220M
Cap. Flow
-$774M
Cap. Flow %
-40.09%
Top 10 Hldgs %
34.72%
Holding
143
New
28
Increased
19
Reduced
29
Closed
37

Top Buys

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$75.2M
2
HUM icon
Humana
HUM
+$40.6M
3
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$30.6M
4
DVA icon
DaVita
DVA
+$28.5M
5
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$25.6M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$51.8M
2
AZN icon
AstraZeneca
AZN
+$48.2M
3
ABBV icon
AbbVie
ABBV
+$45M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$35M
5
THOR
THORATEC CORPORATION
THOR
+$33.2M

Sector Composition

Rank Sector Weight
1 Healthcare 46.08%
2 Financials 1.16%
3 Technology 0.74%
4 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIRM
51
CALL
DELISTED
Air Methods Corp
AIRM
$7.28M 0.38%
125,000
– –
BAX icon
52
Baxter International
BAX
$11.6B
$7.13M 0.37%
188,703
+161,088
+583% +$5.84M
ARNA
53
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.12M 0.37%
121,658
– –
BCRX icon
54
BioCryst Pharmaceuticals
BCRX
$2.37B
$6.6M 0.34%
868,570
-763,790
-47% -$4.84M
VTRS icon
55
CALL
Viatris
VTRS
$20.1B
$6.51M 0.34%
150,000
– –
LPDX
56
DELISTED
LIPOSCIENCE INC COM
LPDX
$5.88M 0.3%
1,382,350
– –
TPST icon
57
Tempest Therapeutics
TPST
$14.8M
$5.54M 0.29%
207
-1
-0.5% -$27.4K
CASM
58
DELISTED
CAS Medical Systems, Inc.
CASM
$5.44M 0.28%
3,200,000
– –
AERI
59
DELISTED
Aerie Pharmaceuticals
AERI
$5.39M 0.28%
+300,000
New +$3.91M
ANTH
60
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.19M 0.27%
211,482
– –
VYNT
61
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$4.88M 0.25%
+2,361
New +$5.1M
GERN icon
62
Geron
GERN
$911M
$4.74M 0.25%
+1,058,000
New +$4.54M
NUWE icon
63
Nuwellis
NUWE
$189K
– –
0
– –
BIND
64
DELISTED
BIND THERAPEUTICS INC
BIND
$3.87M 0.2%
+256,384
New +$3.26M
CEMP
65
DELISTED
Cempra, Inc.
CEMP
$3.84M 0.2%
309,655
-493,861
-61% -$5.98M
LCAV
66
DELISTED
LCA-VISION INC
LCAV
$2.85M 0.15%
730,856
– –
INFI
67
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$2.76M 0.14%
+200,000
New +$2.82M
OCRX
68
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.74M 0.14%
+211,119
New +$1.97M
GYRE icon
69
Gyre Therapeutics
GYRE
$662M
$2.56M 0.13%
+783
New +$3.09M
KIN
70
DELISTED
Kindred Biosciences, Inc.
KIN
$2.51M 0.13%
+225,000
New +$2.68M
STRM
71
DELISTED
Streamline Health Solutions
STRM
$2.27M 0.12%
+21,667
New +$2.38M
RIGL icon
72
Rigel Pharmaceuticals
RIGL
$680M
$2.18M 0.11%
76,368
-30,405
-28% -$892K
NVDQ
73
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.98M 0.1%
+120,010
New +$1.99M
ARWR icon
74
Arrowhead Research
ARWR
$12.1B
$1.54M 0.08%
+142,017
New +$1.14M
PTN
75
Palatin Technologies
PTN
$13.7M
$1.47M 0.08%
1,600
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q4 2013 Portfolio in Review

As of Q4 2013, Deerfield Management held 143 positions worth $1.93B, down 10% from $2.15B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Deerfield Management withdrew a net $774M in Q4 2013, closing 37 positions and reducing 29 holdings. Its most notable exit was Pfizer, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Humana worth $42.8M.

  • Deerfield Management's largest Q4 2013 buy was Humana: 414,670 shares worth $42.8M.
  • Deerfield Management added most to QUESTCOR PHARMA INC in Q4 2013, an estimated $75.2M increase.
  • Deerfield Management's biggest Q4 2013 reduction was Teva Pharmaceuticals, cutting an estimated $35M.
  • Deerfield Management fully exited Pfizer in Q4 2013, selling an estimated $51.8M.
  • Deerfield Management's ten largest holdings make up 35% of its $1.93B portfolio in Q4 2013.
  • Deerfield Management opened 28 new positions and closed 37 in Q4 2013.
  • Deerfield Management's portfolio value fell 10% quarter-over-quarter to $1.93B.

Based on Deerfield Management's 13F filing for Q4 2013, filed 14 Feb 2014.